The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to beta-Amyloid Oligomer-Related Neurotoxicity and Memory Impairment

Valeriy G. Ostapchenko  
*Western University*

Megan Chen  
*Western University*

Monica S. Guzman  
*Western University*

Yu-Feng Xie  
*University of Manitoba*

Natalie Lavine  
*University of Manitoba*

See next page for additional authors

Follow this and additional works at: [http://ir.lib.uwo.ca/anatomypub](http://ir.lib.uwo.ca/anatomypub)

Part of the [Anatomy Commons](http://ir.lib.uwo.ca/anatomypub), and the [Cell and Developmental Biology Commons](http://ir.lib.uwo.ca/anatomypub)

Citation of this paper:

Ostapchenko, Valeriy G.; Chen, Megan; Guzman, Monica S.; Xie, Yu-Feng; Lavine, Natalie; Fan, Jue; Beraldo, Flavio H.; Martyn, Amanda C.; Belrose, Jillian C.; Mori, Yasuo; MacDonald, John F.; Prado, Vania F.; Prado, Marco A. M.; and Jackson, Michael F., "The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to beta-Amyloid Oligomer-Related Neurotoxicity and Memory Impairment" (2015). Anatomy and Cell Biology Publications. 81.

[http://ir.lib.uwo.ca/anatomypub/81](http://ir.lib.uwo.ca/anatomypub/81)
Neurobiology of Disease

The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to β-Amyloid Oligomer-Related Neurotoxicity and Memory Impairment

Valeriy G. Ostapchenko,1,2* Megan Chen,1* Monica S. Guzman,1,2 Yu-Feng Xie,1,4,5 Natalie Lavine,1,3* Jue Fan,1 Flavio H. Beraldo,1 Amanda C. Martyn,1 Jillian C. Belrose,1 Yasuo Mori,6 John F. MacDonald,1,2,3† Vania F. Prado,1,2,3 Marco A.M. Prado,1,2,3 and Michael F. Jackson1,2,4,5

1Molecular Medicine, Robarts Research Institute, 2Department of Physiology and Pharmacology, Schulich School of Medicine, and 3Department of Anatomy and Cell Biology, Schulich School of Medicine, University of Western Ontario, London, Ontario N6A 5B7, Canada, 4Department of Pharmacology and Therapeutics, College of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0T6, Canada, 5Neuroscience Research Group, Kleysen Institute for Advanced Medicine, University of Manitoba, Winnipeg, Manitoba R3E 3J7, Canada, and 6Laboratory of Molecular Biology, Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Kyoto 615-8510, Japan

In Alzheimer’s disease, accumulation of soluble oligomers of β-amyloid peptide is known to be highly toxic, causing disturbances in synaptic activity and neuronal death. Multiple studies relate these effects to increased oxidative stress and aberrant activity of calcium-permeable cation channels leading to calcium imbalance. The transient receptor potential melastatin 2 (TRPM2) channel, a Ca2+ permeable nonselective cation channel activated by oxidative stress, has been implicated in neurodegenerative diseases, and more recently in amyloid-induced toxicity. Here we show that the function of TRPM2 is augmented by treatment of cultured neurons with β-amyloid oligomers. Aged APP/PS1 Alzheimer’s mouse model showed increased levels of endoplasmic reticulum stress markers, protein disulfide isomerase and phosphorylated eukaryotic initiation factor 2α, as well as decreased levels of the presynaptic marker synaptophysin. Elimination of TRPM2 in APP/PS1 mice corrected these abnormal responses without affecting plaque burden. These effects of TRPM2 seem to be selective for β-amyloid toxicity, as ER stress responses to thapsigargin or tunicamycin in TRPM2−/− neurons was identical to that of wild-type neurons. Moreover, reduced microglial activation was observed in TRPM2−/−/APP/PS1 hippocampus compared with APP/PS1 mice. In addition, age-dependent spatial memory deficits in APP/PS1 mice were reversed in TRPM2−/−/APP/PS1 mice. These results reveal the importance of TRPM2 for β-amyloid neuronal toxicity, suggesting that TRPM2 activity could be potentially targeted to improve outcomes in Alzheimer’s disease.

Key words: Alzheimer’s disease; β-amyloid; cognitive impairment; mouse model; neurotoxicity; TRPM2

Significance Statement
Transient receptor potential melastatin 2 (TRPM2) is an oxidative stress sensing calcium-permeable channel that is thought to contribute to calcium dysregulation associated with neurodegenerative diseases, including Alzheimer’s disease. Here we show that oligomeric β-amyloid, the toxic peptide in Alzheimer’s disease, facilitates TRPM2 channel activation. In mice designed to model Alzheimer’s disease, genetic elimination of TRPM2 normalized deficits in synaptic markers in aged mice. Moreover, the absence of TRPM2 improved age-dependent spatial memory deficits observed in Alzheimer’s mice. Our results reveal the importance of TRPM2 for neuronal toxicity and memory impairments in an Alzheimer’s mouse model and suggest that TRPM2 could be targeted for the development of therapeutic agents effective in the treatment of dementia.

Introduction
In Alzheimer’s disease (AD), a progressive biochemical cascade leading to neuronal dysfunction takes place many years before the appearance of cognitive deficits (Selkoe, 2011). These alterations derive at least in part from the accumulation of β-amyloid peptides (Aβ) whose toxicity depends on its interactions with distinct cell surface proteins. These include, but are not limited to, the prion protein (Laurén et al., 2009; Caetano et al., 2011; Ostapchenko et al., 2013b), NMDAR (Snyder et al., 2005; Decker et al., 2010; Malinow, 2012; You et al., 2012), mGluR5 (Renner et al., 2010), and α7 nicotinic acetylcholine receptors (α7nAChRs) (Wang et al., 2000). Although precise mechanisms of toxicity remain unknown, dysregulation of
Ca\(^{2+}\) homeostasis is widely accepted as being intimately associated with A\(\beta\) toxicity (LaFerla, 2002; Mattson, 2004). In light of the marked toxicity of A\(\beta\) toward glutamate synapses (Lambert et al., 1998; Walsh et al., 2002; Lacor et al., 2007; Laurant et al., 2009; Ma et al., 2009; Ferreira and Klein, 2011), one particularly attractive candidate mechanism contributing to Ca\(^{2+}\) dysregulation in AD is via NMDARs (De Felice et al., 2007). However, block of NMDARs as a therapeutic avenue is problematic as this can impair learning and memory (Newcomer et al., 1999; Rammsayer, 2001), cause psychotic-like symptoms in patients (Lahti et al., 1995; Breier et al., 1997; Newcomer et al., 1999), and exacerbate neurodegeneration (Ikonomidou et al., 2000). Identifying secondary sources of Ca\(^{2+}\) entry, recruited downstream of aberrant NMDAR activation, may provide attractive alternative targets for novel AD therapeutics.

Transient receptor potential melastatin 2 (TRPM2) is a Ca\(^{2+}\)-permeable nonselective cation channel most highly expressed in the CNS (Fonfria et al., 2006a; Olah et al., 2009; Bai and Lipski, 2010). Notably, TRPM2 is reported to modulate neuronal vulnerability to ischemia (Bai and Lipski, 2010; Alim et al., 2013), and a variant of TRPM2 has been linked to neurodegenerative diseases (Hermosura et al., 2008). Functionally, TRPM2 channel opening is coupled to oxidative stress via the production of ADP-ribose (ADPR), an intracellular TRPM2 agonist (Knowles et al., 2013). However, ADPR alone is insufficient to gate TRPM2 channels; rather channel activation is contingent on the binding of Ca\(^{2+}\) to an intracellular channel domain (Tong et al., 2006). In this regard, we recently showed that TRPM2 channels are intimately coupled to NMDARs via Ca\(^{2+}\) influx (Olah et al., 2009) and are necessary for the induction of NMDAR-dependent long-term depression (Xie et al., 2011).

Here we show that A\(\beta\) oligomers (A\(\beta\)Os) augment TRPM2 currents in cultured neurons. Moreover, the absence of TRPM2 decreases endoplasmic reticulum (ER) stress and abnormal microglial activation in TRPM2\(^{-/-}\)/APP/PS1 mice, without affecting plaque burden. Critically, elimination of TRPM2 rescues cognitive deficits observed in aged AD model mice and suggest that this channel represents a new therapeutic target in AD.

**Materials and Methods**

**Animals.** TRPM2-null mice (TRPM2\(^{-/-}\)) were generated in a C57BL/6J background as described previously (Yamamoto et al., 2008). Wild-type and TRPM2\(^{-/-}\) mice were derived from heterozygous mating. Genotyping was successfully described (Yamamoto et al., 2008). The APP/PS1 mouse model of AD, carrying the genes of human APP-Swedish mutation and the \(\Delta E9\) mutation of the human presenilin 1 (Jankowsky et al., 2003), in a C57BL/6J background was obtained from The Jackson Laboratory (stock #005864). TRPM2\(^{-/-}\) mice were crossed to APP/PS1 and the offspring intercrossed to generate the desired genotypes. Mouse cohorts of desired genotypes were generated and used longitudinally for behavioral analysis. Randomized littermates were used for behavioral analysis. Only male mice were used; and in all experiments, the experimenter was blind to the genotypes. All animal experiments were conducted with approval from the University of Western Ontario Animal Use Subcommittee (2008-127). Once the mouse cohorts reached 20–24 months, they were killed and used for biochemical and pathological analysis.

**Electrophysiology.** Primary cultured hippocampal neurons were derived from time-pregnant CD1 or C57BL/6J or TRPM2\(^{-/-}\) mice at E18 as previously described (Xie et al., 2011). Whole-cell voltage-clamp recordings were performed from neurons (14–21 DIV) treated for 24 h with control medium or medium containing A\(\beta\)Os (1 \(\mu\)M), which is neurotoxic (Ostapchenko et al., 2013b). A\(\beta\)Os were prepared and routinely checked by Western blotting as described previously (Ostapchenko et al., 2013b). In short, synthetic A\(\beta\)(1–42) peptide (rPeptide) was monomerized in hexafluorosipropionan, reconstituted in DMSO, and diluted in PBS to a final concentration of 100 \(\mu\)M. Oligomers were allowed to form for 24 h at 4°C and were then used for experiments. For recording, the intracellular solution contained the following (in mM): 150 cesium gluconate, 10 HEPES, and 1 ADPR. Standard extracellular solution contained the following (in mM): 140 NaCl, 5.4 KCl, 2.5 CaCl\(_2\), 0.003 t-serine, and 0.0002 TTX. ADPR-dependent TRPM2 currents were evoked in response to repeated applications of 100 \(\mu\)M NMDA (10 s, repeated every 6 s) using a multibarreled rapid perfusion system (SF-77B; Warner Instruments). Once TRPM2 currents stabilized, a calcium free solution was applied to inactivate TRPM2 channels (total divalent concentration was maintained by replacing CaCl\(_2\) with equimolar BaCl\(_2\)). Data were filtered at 2 kHz, digitized, and acquired using pCLAMP and Axoscope software (Molecular Devices).

**Real-time quantitative PCR.** RNAs from WT and TRPM2\(^{-/-}\) hippocampi (three for each genotype) were purified as previously described (Ostapchenko et al., 2013a). To quantify expression levels of interest, RNA samples were amplified in real-time quantitative PCR using the following primers: *Trpm2* (forward, CGTGTCCTCGTCTCATG CACA; reverse, ACACAGGATGCCGGTCATGA; forward, TT TACGGTGCCGCTTCTGCT; GluN1 (forward, GAGGCCAATCTCGTGGATA; reverse, TAGACGAGGACT CACC GCCG); GluN2A (forward, GTGAGCTCTGGTGAGGTA; reverse, TATCGAGGCTCCTCAACTCAT); Cav1.2 (forward, AGCTGACAGAC CTCAGTGCC; reverse, AGCTCTGAGGTTTACCGCA C); ChRNA7 (forward, TGGACGAGGAGACTTGGG TGGTAA; reverse, TGGCCGGATGCTCTCGTGAAG). As the reference gene, Pgkl (forward, GCTCGTTGAGGAG TGGTAC; reverse, TGGCCGTCACTTTGAGTCAT). All primers were designed using the following public domain software: Primer3 (version 0.4.0). The expression levels of other genes were measured directly as described above.

**Western blotting, ELISA, and immunohistochemistry.** Mice were anesthetized using ketamine (100 mg/kg) and transcardially perfused with 0.9% saline. For each mouse, the cortex and hippocampus from one hemibrain were used for ELISA and Western blotting analyses; the other hemibrain was postfixed as described below and used for immunofluorescence.

For hippocampus fractionation, tissues were homogenized in 50 mM Tris-HCl, pH 7.2, 200 mM NaCl, 2 mM sodium EDTA, with protease inhibitor cocktail (Millipore), centrifuged at 100,000 \(\times\) g, and the supernatants were used as the Tris-soluble fraction of the proteins. The sediments were resuspended in radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 1% sodium dodecyl sulfate).
dodecyl sulfate) containing protease inhibitor cocktail III (Millipore) and phosphatase inhibitors 10 mM NaF and 0.5 mM Na$_2$VO$_4$, followed by 3 cycles (power 3) of sonication for 10 s with 1 min intervals between the cycles using Sonic Dismembrator M100 (Fisher Scientific) on ice. Samples were centrifuged at 16,000 × g for 30 min, and the supernatants were used as the cellular fraction of the remaining sediments. Remaining sediments were solubilized in 5 M guanidine-HCl, 50 mM HEPES, pH 7.5, 3 mM EDTA, followed by rotation at room temperature for 3 h, and used as insoluble protein fraction. Protein concentration was measured using the Bradford assay.

For Western blotting, a total of 30 μg of each sample was resolved by electrophoresis in SDS-polyacrylamide gels using 13.5% Tris-tricine gels or 4%–12% PAGE gels (Lonza), followed by a standard blotting procedure using anti-protein disulfide isomerase (PDI) (1:1000, catalog #3501), anti-synaptophysin (1:2000, catalog #5467, both Cell Signaling Technology), or anti β-amyloid (6E10, 1:2000, Covance) antibodies. ELISA was performed using the kit for human Aβ(1–42) (catalog #KHB3544, Invitrogen). Tris-soluble and insoluble fractions were diluted 30- and 500-fold in dilution buffer and the Aβ(1–42) concentration was measured using synthetic peptide as a standard.

For immunohistochemistry, hemibrains were postfixed for 48 h with 4% PFA in phosphate-buffered saline. Coronal sections (50 μm) were cut using a vibratome. Polyclonal anti-human Aβ antibody (catalog #44344, Invitrogen), anti-pepF2a (Ser51) antibody (catalog #9721, Cell Signaling Technology), anti-Synaptophysin antibody (catalog #sc-9116, Santa Cruz Biotechnology), and anti-Iba1 antibody (catalog #PAS-27436, Thermo Fisher Scientific) were used on free-floating sections. Aβ was retrieved by boiling the sections in 10 mM sodium citrate buffer.

For Western blotting, a total of 30 μg of each sample was resolved by electrophoresis in SDS-PAGE gel at 20 mA. Briefer blotting was done as described above. Anti-puromycin (clone 12D10, Millipore) was used at 1 μg/ml.

Elevated plus maze and locomotor activity. Anxiety-like behavior was assessed using the elevated plus maze test, performed as described previously (Martins-Silva et al., 2011). Sessions were recorded and analyzed using the ANY-Maze software (Stoelting) to determine total time spent in the open and closed arms. Spontaneous locomotor activity in a new environment, a measure of exploratory behavior, was recorded using automated locomotor boxes as described previously (Guzman et al., 2011).

Results

Aβ oligomer treatment sensitizes ADPR-dependent TRPM2 currents generated by repeated NMDAR stimulation

We previously reported that repeated applications of NMDA to cultured hippocampal neurons initiate the development of large ADPR-dependent TRPM2 currents (Olah et al., 2009; Belrose et al., 2012). To investigate whether TRPM2 channel function can be modulated by AβOIs, we treated cultured hippocampal neurons for 24 h with AβOs, a procedure known to increase neuronal death (Kudo et al., 2012; Ostapchenko et al., 2013b). As shown in Figure 1A, B, NMDA-induced TRPM2 currents were augmented by AβO treatment.

Decreased levels of ER stress in brains of APP/PS1 mice lacking TRPM2

To study the influence of TRPM2 channels on Aβ neuronal toxicity, we crossed APP/PS1 mice (Jankowsky et al., 2003) to TRPM2$^{−/−}$ mice (Yamamoto et al., 2008). The offspring were then intercrossed to generate the four genotypes used in this study (WT, TRPM2$^{−/−}$, APP/PS1, and TRPM2$^{−/−}$/APP/PS1).

In AD patients and AD mouse models, increased protein misfolding leads to ER stress and the activation of the unfolded protein response (Matus et al., 2011; Scheper et al., 2011; Hetz and Mollereau, 2014). Among ER stress proteins, PDI has been found increased in the brain of AD patients (Kim et al., 2000; Andreu et al., 2012). Using immunoblots, we tested whether expression of PDI is changed in the hippocampus of 20- to 24-month-old APP/PS1 and
TRPM2−/−/APP/PS1 mice compared with WT controls. Similar to previous reports in AD patients, APP/PS1 mice showed increased levels of PDI (Fig. 1C,D). In contrast, the levels of PDI in TRPM2−/−/APP/PS1 mice were no different from that of WT controls or TRPM2−/− mice (Fig. 1C,D).

Increased phosphorylation of the eukaryotic initiation factor 2α (eIF2α) at Ser51 in response to ER stress inhibits global protein translation and contributes to synaptic pathophysiology in the APP/PS1 mouse model of AD (Yasuda et al., 2002; Ma et al., 2013). We therefore tested whether the absence of TRPM2 could prevent changes in eIF2α phosphorylation in neurons of APP/PS1 mice. To specifically compare the response in neurons, we used immunofluorescence and quantified the staining of neuron-rich hippocampal areas. In areas CA1, CA2, and CA3 of the hippocampus of APP/PS1 mice, pSer51-eIF2α immunoreactivity was higher compared with wild-type controls (Fig. 1E,F). Conversely, in TRPM2−/−/APP/PS1 mice, hippocampal pSer51-eIF2α immunoreactivity was similar to the levels found in the hippocampus of TRPM2−/− mice (Fig. 1E,F).

**TRPM2−/− neurons do not have altered ER stress responses or major compensatory responses**

To examine the possibility that ER stress responses in general are altered in TRPM2−/− neurons, the response to ER stressors, thapsigargin (Tg) or tunicamycin (Tn), was determined by monitoring the changes in the expression levels of pSer51-eIF2α and...
Grp78/BiP, an ER chaperone and master regulator of ER stress. In cultured hippocampal neurons from both WT and TRPM2^{−/−}, Tg or Tn treatment resulted in increased levels of pSer51-eIF2α and Grp78/BiP. No difference in the ER stress response between genotypes was observed (Fig. 2A–D). Consistent with the increased levels of pSer51-eIF2α in response to ER stress, general protein translation, determined using nonradioactive SUnSET, was reduced by treatment with Tg. Again, no difference in this response was observed in the absence of TRPM2 compared with control neurons (Fig. 2E, F).

To further examine whether the absence of TRPM2 can elicit compensatory responses in transcripts that regulate pathways related to Ca^{2+}-induced toxicity, we used qRT-PCR. We tested the expression of genes previously linked to NMDAR/AMPAR excitotoxicity in the hippocampus of controls and TRPM2^{−/−} mice. For NMDAR subunits, we limited our analysis to GluN1, GluN2A, and GluN2B, the most highly expressed subtypes in the adult hippocampus and cortex (Monyer et al., 1994). We also measured transcript levels of the AMPAR subunit GluA2, inclusion of which renders AMPARs Ca^{2+}-impermeable, and of genes implicated in Ca^{2+} dysregulation in AD (Demuro et al., 2010), including the α7 nicotinic acetylcholine receptor and L-type voltage-gated Ca^{2+} channels (CaV1.2). Last, as TRPM7 and TRPM2 expression has previously been suggested to be interdependent (Aarts et al., 2003), we examine whether TRPM7 expression was altered in TRPM2^{−/−} mice. qRT-PCR analysis of hippocampal extracts from WT and TRPM2^{−/−} mice confirmed the absence of TRPM2 mRNA in TRPM2^{−/−} mice (Fig. 2G). There were no changes in the hippocampal mRNA levels of NMDA receptor subunits (i.e., GluN1, GluN2A, and GluN2B), GluA2, α7 nicotinic acetylcholine receptor CaV1.2, or TRPM7 (Fig. 2G).

**Prevention of synapse loss in APP/PS1 mice lacking TRPM2**

Given that synapse loss and decreased levels of synaptic proteins are early correlates of AD severity (Pozueta et al., 2013), we compared the expression levels of the synaptic marker synaptophysin in the hippocampus of APP/PS1 mice with that of TRPM2^{−/−}/APP/PS1 mutants. Immunofluorescence analysis showed that synaptophysin levels were decreased in the hippocampus of APP/PS1 mice compared with WT controls. On the other hand, synaptophysin staining in the hippocampus of TRPM2^{−/−}/APP/PS1 mutants was similar to that observed for WT controls (Fig. 3A–D). Likewise, labeling of synaptophysin in the hippocampus of TRPM2^{−/−} was not different from WT controls (Fig. 3A–D). These results suggest that elimination of

---

**Figure 2.** TRPM2^{−/−} neurons do not have altered ER stress responses or major compensatory responses. A–D, Representative immunoblots of wild-type (A) and TRPM2^{−/−} (B) primary hippocampal neuronal cultures, nontreated or treated with thapsigargin (Tg) or tunicamycin (Tn) as described in Materials and Methods. Analysis of p(S51)-eIF2α (C) and GRP78/BiP (D) levels. At least six samples were analyzed for each condition. For each treatment condition (Tg or Tn), data were analyzed with Student’s t test. E, F, SUnSET assay of protein synthesis in control and thapsigargin-treated cultured hippocampal neurons. E, Representative blots. F, Analysis of puromycin immunostaining was done for three samples for each condition. Data were analyzed with Student’s t test. G, qRT-PCR comparison of hippocampal mRNA levels of TRPM2, TRPM7, GluN1, GluN2A, GluN2B, GluA2, Cav 1.2, and α7NACHR in WT and TRPM2^{−/−} mice. Data were collected from three samples for each genotype, normalized by Pgk1 mRNA levels, and analyzed with Student’s t test.

---

Grp78/BiP, an ER chaperone and master regulator of ER stress. In cultured hippocampal neurons from both WT and TRPM2^{−/−}, Tg or Tn treatment resulted in increased levels of pSer51-eIF2α and Grp78/BiP. No difference in the ER stress response between genotypes was observed (Fig. 2A–D). Consistent with the increased levels of pSer51-eIF2α in response to ER stress, general protein translation, determined using nonradioactive SUnSET, was reduced by treatment with Tg. Again, no difference in this response was observed in the absence of TRPM2 compared with control neurons (Fig. 2E, F).

To further examine whether the absence of TRPM2 can elicit compensatory responses in transcripts that regulate pathways related to Ca^{2+}-induced toxicity, we used qRT-PCR. We tested the expression of genes previously linked to NMDAR/AMPAR excitotoxicity in the hippocampus of controls and TRPM2^{−/−} mice. For NMDAR subunits, we limited our analysis to GluN1, GluN2A, and GluN2B, the most highly expressed subtypes in the adult hippocampus and cortex (Monyer et al., 1994). We also measured transcript levels of the AMPAR subunit GluA2, inclusion of which renders AMPARs Ca^{2+}-impermeable, and of genes implicated in Ca^{2+} dysregulation in AD (Demuro et al., 2010), including the α7 nicotinic acetylcholine receptor and L-type voltage-gated Ca^{2+} channels (CaV1.2). Last, as TRPM7 and TRPM2 expression has previously been suggested to be interdependent (Aarts et al., 2003), we examine whether TRPM7 expression was altered in TRPM2^{−/−} mice. qRT-PCR analysis of hippocampal extracts from WT and TRPM2^{−/−} mice confirmed the absence of TRPM2 mRNA in TRPM2^{−/−} mice (Fig. 2G). There were no changes in the hippocampal mRNA levels of NMDA receptor subunits (i.e., GluN1, GluN2A, and GluN2B), GluA2, α7 nicotinic acetylcholine receptor CaV1.2, or TRPM7 (Fig. 2G).
TRPM2 prevents the decrease in synaptophysin levels observed in the brains of 20- to 24-month-old APP/PS1 mice.

Decreased microglial activation in APP/PS1 mice lacking TRPM2

We tested whether the absence of TRPM2 affects microglial activation in APP/PS1 mice by measuring Iba1 immunostaining, a marker of microglia. Our analysis shows that, while Iba1 immunoreactivity was increased in the hippocampus of APP/PS1 mice compared with WT controls, there was no difference in Iba1 staining when comparing TRPM2−/−/APP/PS1 mutants with WT controls (Fig. 4A, B). These results suggest that, while brains of APP/PS1 mice show increased microglial response, this response is absent in the brains of TRPM2−/−/APP/PS1 mutants. Together, these data provide multiple lines of evidence demonstrating that elimination of TRPM2 expression improves endpoints related to pathological hallmarks in APP/PS1 mice.

TRPM2 elimination does not change plaques or soluble Aβ peptides but slightly decreases the levels of small molecular weight oligomers

It is possible that the absence of TRPM2 could influence amyloid processing and accumulation, which may contribute to altered levels of ER stress markers. Hence, we analyzed Aβ(1–42) levels in soluble, membrane-bound and insoluble amyloid plaque-associated fractions of hippocampal proteins. We did not detect any difference between APP/PS1 or TRPM2−/−/APP/PS1 mutants when comparing them for Aβ(1–42) immunofluorescence staining or thioflavin S-positive plaques (Fig. 5 A, B). Similarly, ELISA determination of Aβ(1–42) content in insoluble and Tris-soluble fractions from APP/PS1 and TRPM2−/−/APP/PS1 hippocampal samples showed no change (Fig. 5C, D). To further investigate whether different oligomeric fractions of Aβ peptides may be affected by lack of TRPM2, we resolved low molecular weight oligomers by Tris-tricine gel electrophoresis of hippocampal lysates. These experiments revealed a decreased amount of Aβ trimers and tetramers in RIPA-soluble fractions of TRPM2−/−/APP/PS1 hippocampi compared with APP/PS1 mice (Fig. 5E). As overall Aβ peptides and amyloid plaques are not affected by lack of TRPM2, the decreased levels of cell-associated low molecular weight AβOs detected in TRPM2−/−/APP/PS1 mutants may reflect decreased cellular stress level compared with APP/PS1 mice. This may improve the turnover of misfolded proteins and, therefore, cell-bound AβOs.

Elimination of TRPM2 in APP/PS1 mice does not change age-related hypoactivity

To determine whether improved AD pathological hallmarks observed in APP/PS1 mice lacking TRPM2 channels translates into improved behavioral performance, we compared the performance of TRPM2−/−/APP/PS1 mutants with that of APP/PS1, WT, and TRPM2−/− controls. Importantly, the tests were performed longitudinally in the same cohort of mice at different time points, so that we could evaluate age-related progression of behavior deficits.

As hypoactivity is frequently observed both in human AD patients and transgenic mouse models of AD (Ferguson et al., 2013; Iqbal et al., 2013), we investigated locomotor activity using automated open field chambers. Locomotor activity was recorded at 3, 6, 9, 12, and 15 months of age. We detected no difference in activity in the four genotypes until 12 months of age (Fig. 6A). At 12–15 months of age, both APP/PS1 and TRPM2−/−/APP/PS1 mutants showed decreased locomotor activity compared with WT controls and TRPM2−/− mice [Fig. 6A; two-way ANOVA, significant main effect of APP/PS1 carriers: F(1,33) = 11.12, p = 0.0021; no differences between noncarriers (WT and TRPM2−/−): F(1,33) = 0.9240, p = 0.3438; and no interaction]. These results suggest that the hypoactivity phenotype was not affected by ablation of TRPM2 channels.

To test for anxiety behaviors, we performed the elevated plus-maze task (Fig. 6B). There were no differences in the time spent in the open arms among the four mouse genotypes (representative result for 15-month-old mice, ANOVA, no effect of APP/PS1 carriers: F(1,38) = 0.7546, p = 0.3905; no differences between noncarriers (WT and TRPM2−/−): F(1,38) = 0.1139, p = 0.7376; and no interaction). Hence, the APP/PS1 transgenes did not affect anxiety-like behavior. Moreover, TRPM2 elimination did not affect anxiety-like behavior.

Elimination of TRPM2 in APP/PS1 mice rescues spatial memory deficits

To test whether loss of TRPM2 had any effect on cognitive deficits in APP/PS1 mice, we used two spatial memory tests, the Barnes maze and the MWM. We tested mice at 3, 6, 9, 12, and 15 months of age in the Barnes maze and at 12 and 15 months in the MWM. Similar to previous reports (Savonenko et al., 2005), our Barnes maze analysis did not detect consistent spatial memory deficits when APP/PS1 mice were compared with controls until 12 months of age (Fig. 7A–D). However, APP/PS1 mice showed clear spatial deficits in the Barnes maze at 15 months of age (Fig. 7E, F). It is important to note that, because of the longitudinal nature of the study, the same cohort of mice was tested in the...
Barnes maze at 5 different time points. Even though the location of the target hole was changed between tests, analysis of latency time to reach the target hole suggests that mice from all genotypes seem to remember the “task rules” as they performed well already on the first day of training from 6 months up to 12 months (Fig. 7A, B). Probe trials at 12 months showed no differences among genotypes for either the number of times mice visited the target hole or the target role preference index (Fig. 7C, D). At 15 months of age, no differences were observed among genotypes in the number of errors made before reaching the target hole (Fig. 7A), but mice carrying the APP/PS1 transgenes presented longer latencies to first visit the target hole than control mice [two-way repeated-measures ANOVA, significant main effect of genotype: \( F_{(3,117)} = 4.883, p = 0.006 \), post hoc analysis showed significant differences, \( p < 0.05 \), when noncarriers (WT and TRPM2 \(^{-/-}\)) were compared with carriers (TRPM2 \(^{-/-}\)/APP/PS1 and APP/PS1)]. Fig. 7B). Considering that both APP/PS1 and TRPM2 \(^{-/-}\)/APP/PS1 mice showed decreased locomotor activity and TRPM2 \(^{-/-}\) compared with TRPM2 \(^{-/-}\)/APP/PS1 and APP/PS1). Analysis of the distance traveled to find the target at 12 months (Fig. 7B) or 15 months (Fig. 7F) indicated significant main effects of genotype (12 months: two-way repeated-measures ANOVA, \( F_{(3,126)} = 4.531, p = 0.0077 \); 15 months: two-way repeated-measures ANOVA, \( F_{(3,126)} = 4.167, p = 0.0118 \) and day (12 months: two-way repeated-measures ANOVA, \( F_{(3,126)} = 25.90, p < 0.0001 \); 15 months: two-way repeated-measures ANOVA, \( F_{(3,117)} = 11.55, p < 0.0001 \)). Overall, mice carrying the APP/PS1 transgenes, independent of the presence or absence of TRPM2, exhibited increased path lengths. However, at day 4, the performance of all genotypes was identical both at 12- and 15-month old mice. Additionally, swim speed analysis showed no differences in performance among genotypes at 12 months (Fig. 8G; two-way repeated-measures ANOVA, no differences in genotype: \( F_{(3,123)} = 0.5156, p = 0.6738 \)) or 15 months (Fig. 8G; two-way repeated-measures ANOVA, no differences in genotype: \( F_{(3,123)} = 0.5156, p = 0.6738 \)).
indicating that differences observed in the MWM between mice expressing the APP/PS1 transgenes compared with those without it are not due to the decreased physical activity in the pool. Together, these results suggest that 12- and 15-month-old mice carrying the APP/PS1 transgenes showed difficulties learning the MWM spatial task as they took longer than WT and \( \text{TRPM2}\)/APP/PS1 to learn the location of the platform; however, the deficit did not seem to be extensive, as it disappeared after repetitive training.

The MWM probe trial in 12-month-old mice showed no significant differences among genotypes (Fig. 8D) and a significant main effect of quadrant (\( F(3,140) = 52.178, p = 0.001 \)). Further analysis indicated that all genotypes spent more time in the target quadrant than in any other quadrant (\( p < 0.001 \), for Target vs opposite, Target vs right, and Target vs left). Analysis of the percentage of time searching in the target quadrant showed no differences in memory retention among the four genotypes (\( F(3,35) = 0.3544, p = 0.7863 \)). These results indicate that there are no memory impairments in any of the mouse groups at 12 months. At 15 months (Fig. 8H), the results showed that APP/PS1 mice spent significantly less time in the target area than the other genotypes (\( F(3,39) = 5.887, p = 0.0020, \) post hoc analysis: \( p = 0.05 \) vs \( \text{TRPM2}\)/APP/PS1, WT, and \( \text{TRPM2}\)/APP/PS1), whereas \( \text{TRPM2}\)/APP/PS1 mice performed similarly to the WT animals (\( p > 0.05 \)). These results show that 15-month-old APP/PS1 mice were unable to recall where the platform was located, and this spatial memory deficit was rescued in \( \text{TRPM2}\)/APP/PS1 mice.

In conclusion, Barnes maze and MWM results indicate that APP/PS1 mice present clear age-dependent spatial memory deficits and that elimination of TRPM2 channels ameliorates these deficits.

**Figure 5.** Normal plaque load in brains of \( \text{TRPM2}^{--}\)/APP/PS1 mice. \( A, B \), Brain slices were stained for plaques with anti-A\( \beta\)1–42 IgG (A) and thioflavin S (B). At least four coronal slices from each mouse brain and at least three brains of APP/PS1 and \( \text{TRPM2}^{--}\)/APP/PS1 mice were used for each immunostaining experiment. \( C, D \), Levels of A\( \beta\)1–42 of insoluble (C) and Tris-soluble (D) fractions of at least 6 hippocampi of APP/PS1 and \( \text{TRPM2}^{--}\)/APP/PS1 mice were analyzed by ELISA. \( E \), Western blot analysis of intracellular and cell membrane-bound fractions of hippocampus. The lower band corresponds to the trimers, and the upper band to the tetramers of A\( \beta\)1–42. At least five extracts obtained from each genotype were analyzed. *\( p < 0.05 \) (Student’s t test).

**Figure 6.** Elimination of TRPM2 in APP/PS1 mice does not change age-related hypoactivity or anxiety. \( A \), Exploratory activity in the open field test of 3- to 15-month-old mice. At 15 months, carriers of APP/PS1 transgenes show decreased locomotion compared with noncarriers. \( B \), Representative elevated plus maze exploration of 15-month-old mice. Bars represent the percentage of time spent by the four genotypes in the Open Arm of the maze. *\( p < 0.05 \). N for WT = 8 –12, N for \( \text{TRPM2}^{--}\) = 7–10, N for APP/PS1 = 10 or 11, N for \( \text{TRPM2}^{--}/\text{APP/PS1} \) = 10 or 11.

\( F(3,117) = 0.9244, p = 0.4380 \), indicating that differences observed in the MWM between mice expressing the APP/PS1 transgenes compared with those without it are not due to the decreased physical activity in the pool. Together, these results suggest that 12- and 15-month-old mice carrying the APP/PS1 transgenes showed difficulties learning the MWM spatial task as they took longer than WT and \( \text{TRPM2}^{--}\)/APP/PS1 to learn the location of the platform; however, the deficit did not seem to be extensive, as it disappeared after repetitive training.

The MWM probe trial in 12-month-old mice showed no significant differences among genotypes (Fig. 8D) and a significant main effect of quadrant (\( F(3,140) = 52.178, p = 0.001 \)). Further analysis indicated that all genotypes spent more time in the target quadrant than in any other quadrant (\( p < 0.001 \), for Target vs opposite, Target vs right, and Target vs left). Analysis of the percentage of time searching in the target quadrant showed no differences in memory retention among the four genotypes (\( F(3,35) = 0.3544, p = 0.7863 \)). These results indicate that there are no memory impairments in any of the mouse groups at 12 months. At 15 months (Fig. 8H), the results showed that APP/PS1 mice spent significantly less time in the target area than the other genotypes (\( F(3,39) = 5.887, p = 0.0020, \) post hoc analysis: \( p < 0.05 \) vs \( \text{TRPM2}^{--}\)/APP/PS1, WT, and \( \text{TRPM2}^{--}\)/APP/PS1), whereas \( \text{TRPM2}^{--}\)/APP/PS1 mice performed similarly to the WT animals (\( p > 0.05 \)). These results show that 15-month-old APP/PS1 mice were unable to recall where the platform was located, and this spatial memory deficit was rescued in \( \text{TRPM2}^{--}\)/APP/PS1 mice.

In conclusion, Barnes maze and MWM results indicate that APP/PS1 mice present clear age-dependent spatial memory deficits and that elimination of TRPM2 channels ameliorates these deficits.
The importance of TRPM2 to CNS function is underscored by studies implicating TRPM2 in diseases, including stroke/ischemia (Jia et al., 2011; Verma et al., 2012; Alim et al., 2013), neurodegenerative diseases (Fonfría et al., 2005; Hermosura et al., 2008), bipolar disorder (Xu et al., 2006; Jang et al., 2015), and epilepsy (Katano et al., 2012). These studies suggest that abnormal TRPM2 activity can profoundly influence CNS function and pathology. We now show that Aβ oligomers can facilitate TRPM2 channel function and that elimination of TRPM2 can reverse pathological and behavioral deficits observed in the AD mouse model APP/PS1.

APP/PS1 mice are considered a less aggressive model of Aβ toxicity, probably reflecting a prodromal phase of AD (Ashe and Zahs, 2010; Ferretti et al., 2012). Starting at 6 months of age, APP/PS1 present significant amounts of soluble and plaque-associated Aβ (Savonenko et al., 2005; Ostapchenko et al., 2013a). Most transgenic AD mouse models present spatial learning and memory deficits, as assessed by MWM performance (Webster et al., 2014) or by Barnes maze (O’Leary and Brown, 2009). However, there are discrepancies for when these deficits first manifest (Ding et al., 2008; Timmer et al., 2010). Our experiments suggest that the performance of APP/PS1 mice on a battery of behavioral tasks cannot be distinguished from that of control mice until reaching 12–15 months of age. At this time, APP/PS1 mice exhibit spatial memory deficits in both MWM and Barnes maze tasks compared with wild-type counterparts. Importantly, elimination of TRPM2 channels ameliorated these deficits. The improved performance in both the Barnes maze and MWM tests with loss of TRPM2 expression in APP/PS1 is not related to changes in physical activity as both mouse lines showed similar levels of activity at all ages tested. Nonetheless, APP/PS1 mice, with or without TRPM2 expressed, showed decreased activity by 12–15 months of age, which corroborate previous findings (Ferguson et al., 2013). Although ablation of TRPM2 channels improved many AD pathology hallmarks in APP/PS1 mice, it did not improve the hypoactivity phenotype. This hypoactivity could be the result of Aβ-derived disturbances in muscular function (Mukhamedyarov et al., 2014). Indeed, Aβ peptides are elevated in skeletal muscles of AD patients (Kuo et al., 2000), where they have been suggested to cause membrane depolarization in fibers by inhibiting the Na\(^+\)/K\(^+\)-ATPase and by forming membrane pores (Mukhamedyarov et al., 2011, 2014). Moreover, Aβ oligomers have been detected in the muscle fibers of sporadic inclusion body myositis patients (Nogalska et al., 2010). TRPM2 expression in skeletal muscles is low (Fonfría et al., 2006a), which might explain the lack of improvement in AD-related hypoactivity.

Although the precise mechanisms underlying the improvement of spatial memory deficits by removal of TRPM2 are unknown, they are likely related to the reduced pathological markers noted in aged TRPM2\(^{-/-}\)/APP/PS1 compared with APP/PS1 mice. The longitudinal design of our study precluded biochemical and histological analyses at time points corresponding with behavioral assays. Nevertheless, similar to AD patients (Kim et al., 2000; Andreu et al., 2012), the brains of 20- to 24-month-old APP/PS1 mice present upregulated PDI and increased phosphorylation of eIF2α, two molecular markers of ER stress (Matus et al., 2011; Scheper et al., 2011; Hetz and Mollereau, 2014). Interestingly, levels of pSer51-eIF2α immunoreactivity in TRPM2\(^{-/-}\)/mouse were slightly higher than in controls, but not due to increased ER stress, as PDI levels between these two genotypes were not different. Additionally, 20- to 24-month-old APP/PS1 mice presented decreased levels of synaptophysin and increased levels of Iba1, suggesting that their brains presented synaptic loss and increased microglial activation. Brains of 20- to 24-month-old APP/PS1 mouse lacking TRPM2 channels (TRPM2\(^{-/-}\)/APP/PS1 mice) did not show any of these deficits, indicating that removal of the Ca\(^{2+}\)-permeable oxidative stress sensor TRPM2 can help to normalize the unfolded protein response and thereby moderate ER stress, synaptic loss, and inflammation in AD mice. In agreement with this possibility, in the absence of TRPM2, we did not detect abnormal expression of other genes that could regulate Ca\(^{2+}\) dynamics. Interestingly, the fact that elimination of TRPM2 does not affect ER stress responses due to thapsigargin and tunicamycin treatment suggests that TRPM2 elimination does not affect ER stress responses indiscriminately but rather is selective for Aβ-mediated effects.

Other mechanisms may also be at play after TRPM2 removal. For example, genetic ablation of TRPM2 is associated with increased phosphorylation of Akt and inactivation of glycogen synthase kinase GSK3β (Xie et al., 2011; Jang et al., 2015), which was recently found to be beneficial in AD mouse models (Kazim et al., 2014). This effect could balance GSK3β activation by PP2B, a phosphatase whose activity has been directly linked to NMDAR dysregulation by Aβ (Sny-
Therefore, loss of TRPM2 may alter the balance between prosurvival and prodeath signaling in neurons. Also, TRPM2 is present in microglia, where it can activate microglia through ROS- and LPS-mediated signaling, promoting cytokine release and inflammation (Kraft et al., 2004; Fonfria et al., 2005, 2006b; Wehrhahn et al., 2010). AD is also characterized by microglia activation (Kalaria et al., 1996; Dhawan et al., 2012; Ferretti et al., 2012), which we confirm in the present study. Genetic deletion of TRPM2 mitigates this response providing an additional beneficial outcome via reduced neuroinflammation. Last, increasing evidence supports the correlation between cognitive deficits with the levels of soluble AβOs, both in AD patients and AD models (Lesné et al., 2006, 2013; DaRocha-Souto et al., 2011). Although TRPM2 deletion did not change the production of Aβ in APP/PS1 mice, it decreased the amount of small cell membrane-associated AβOs, particularly the trimer and tetramer species. This may consequently reduce Aβ synaptotoxicity (Figuereido et al., 2013; Ostapchenko et al., 2013b).

Several mechanisms through which Aβ peptides augment TRPM2 function can be suggested, including oxidative stress, elevated Ca^{2+} and aberrant NMDAR stimulation (Mattson et al., 1999; De Felice et al., 2007; Malinow, 2012; Um et al., 2012; You et al., 2012). TRPM2 gating by oxidative/nitrosative stress occurs via the production of its agonist, NAD^+/H^+ derived from this source contributes to TRPM2 activation during oxidative stress (Perraud et al., 2005). Aβ-induced oxidative/nitrosative stress, associated with mitochondrial damage (Mattson et al., 1999), may represent one source of ADPR. Alternatively, ADPR production may be stimulated by DNA repair pathways downstream of oxidative/nitrosative stress-induced DNA damage (Park et al., 2014). In addition to ADPR, gating of TRPM2 requires binding of Ca^{2+}/calmodulin to the N terminus of TRPM2 (Tong et al., 2006; Du et al., 2009). We previously reported that ADPR-promoted TRPM2 activation requires Ca^{2+} influx through voltage-gated Ca^{2+} or NMDAR channels (Olah et al., 2009). Coincidentally, Aβ can rapidly associate with excitatory synapses in close proximity, if not directly to NMDARs themselves (Lacor et al., 2004), and provoke Ca^{2+} dysregulation via aberrant NMDAR stimulation (De Felice et al., 2007; Shankar et al., 2008; Li et al., 2011; You et al., 2012). Of note, the action of Aβ peptides upon NMDARs is multifaceted with either increased (Li et al., 2011; You et al., 2012) or decreased function (Snyder et al., 2005; Shankar et al., 2007) having been reported. Reconciling these two opposing functional endpoints, recent evidence suggests that an initial increase in NMDAR function by Aβ treatment is followed by a loss of surface expression and receptor function with extended treatment (Um et al., 2012). Importantly, TRPM2 function can be augmented regardless of the direction of change in NMDAR function as a consequence of intracellular Ca^{2+} elevations and ROS/RNS production associated with Aβ treatment.

It is important to mention that several distinct genetic manipulations in mice have shown promising effects on the toxicity of Aβ peptides or levels of APP metabolites (Lambert et al., 1998; Ohno et al., 2006; Matus et al., 2011; Ma et al., 2013; Jiang et al., 2014). Not all manipulations are expected to lead to therapeutic strategies in humans due to potential experimental limitations. Of note, independent experiments, published during review of our manuscript, have also shown that TRPM2 in endothelial cells in the brain vasculature is a target for Aβ peptides (Park et al., 2014). Particularly, Aβ-induced oxidative stress and DNA damage resulted in overproduction of ADPR, leading to TRPM2 activation and calcium imbalance in cerebrovascular cells and eventually impaired cerebral blood flow. Together with our findings, these results argue that TRPM2 could be a connecting point...
between oxidative stress and cytotoxic effects in AD. Moreover, the improvement in molecular markers of AD pathology and spatial memory deficits in APP/PS1 mice lacking TRPM2 suggests that development of drugs selectively targeting this critical channel could find use for treating AD. Importantly, we did not detect any major behavior deficits in mice lacking TRPM2. In stark contrast to the limited therapeutic index observed for drugs targeting the NMDAR (Farber et al., 2002), this portends the possibility of an improved therapeutic index for drugs aimed at reducing aberrant TRPM2 activation. This is especially important given the paucity of available drugs for treating AD patients.

**References**


clonic epilepsy-related protein EFHC1 interacts with the redox-sensitive TRPM2 channel linked to cell death. Cell Calcium 51:179–185. CrossRef Medline


J. Neurosci., November 11, 2015 • 35(45):15157–15169 • 15169